OXiGENE (OXGN) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-10.2M
Change in fair value of warrants and other financial instruments
Depreciation	16K
Amortization of license agreement
Stock-based compensation	627K
Restricted cash
Prepaid expenses and other current assets	-829K
Accounts payable, accrued expenses and other payables	-618K
Net cash used in operating activities
Changes in other assets
Net cash provided by investing activities
Proceeds from issuance of common stock, net of acquisition costs	0
Proceeds from exercise of employee stock plans
Net cash provided by financing activities
(Decrease) increase in cash and cash equivalents	-22.12M
Cash and cash equivalents at beginning of period	27.29M
Cash and cash equivalents at end of period	5.17M
Fair market value of stock issued in exchange for warrants
Fair market value reclassification of CEFF warrants to equity in connection with warrant exchange
Fair market value of private placement warrants at issuance
Fair market value reclassification of CEFF warrants to liabilities in connection with private placement

Entities mentioned with OXGN

View All Entities